ORLANDO, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. ("RedChip"), an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"™ television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (Nasdaq:AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity.
The interview is now available online at: http://youtu.be/Mpl-mrERQ_0
Aegis Capital has an $11 per share price target on Akers Biosciences, which currently trades at 1.26x book value at $3.70 per share. During the interview, Dr. Akers reconfirms the Company's 2014 revenue guidance of $4 million to $5 million and forecasts 2015 revenues of $7.2 million to $10 million. Akers Biosciences is expected to reach profitability once it reaches $8.8 million in annual sales.
Akers Biosciences' rapid growth phase is being driven by sales of its tests for heparin allergy and cholesterol, as well as its proprietary disposable breathalyzer test.
Heparin is the most widely used anticoagulant and is used for most surgeries and the dissolution of blood clots. Approximately 12 million patients in the U.S. are exposed to heparin annually. Certain patients have life- and limb-threatening allergic reactions to heparin, which lead to worsening of clotting and the development of new clots. Akers Biosciences' heparin allergy test is the only rapid test on the market and produces results in minutes, compared to current laboratory testing which takes days. The Company has secured leading distribution agreements for its heparin allergy test both domestically and internationally, including an initial $1 million order from its distribution partner in China, NovoTek Therapeutics.
The Company's Tri-Cholesterol® diagnostic is currently the only rapid test for Total and HDL Cholesterol and includes an estimate of LDL levels. Rapid results (approx. three minutes) are produced from a convenient finger stick sample that can be used at home or remote locations. These characteristics provide a strong value proposition in developed and emerging countries. During the interview, Dr. Akers comments on a previously announced $864,000 order for its cholesterol test and its potential to solve unmet needs of remote healthcare facilities.
Additional products anticipated to drive revenue for Akers Biosciences in 2015 and beyond include its breath condensate tests for diabetes, asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. The Company also expects to launch its rapid blood test for chlamydia in mid-2015. The test can be administered in the office and produces results in five minutes, which compares to the current standard of care which takes up to a week to receive results. According to the CDC, there were approximately 1.3 million cases of chlamydia reported in the U.S. in 2010.
To watch Dave Gentry's full interview with Dr. Akers, visit: http://youtu.be/Mpl-mrERQ_0
About RedChip Companies, Inc.
RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, which includes: Research Reports, Retail and Institutional Marketing, Institutional and Retail Road Shows, Global Online CEO Conferences, an International TV show, The RedChip Money Report(tm), featuring small-cap companies, airing weekly on Fox Business, Bloomberg Europe, and Bloomberg Asia in over 200 million homes, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media, Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit: http://www.redchip.com/our_services
"Discovering Tomorrow's Blue Chips Today"™
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.